FY2025 · ended Dec 31, 2025 · Revenue $18.79M, +32.7% YoY · Filed Mar 12, 2026
Nephros, Inc. (NEPH) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $18.8 million and net income of $1.2 million. As of Sep 30, 2026 it held $4.5 million in cash and investments and $774,000 in total debt.
Revenue (TTM)
$21.58M
+20.4% vs year-ago TTM
Net income (TTM)
$1.91M
+29.0% vs year-ago TTM
Operating cash flow (TTM)
$-955,000
-135.1% vs year-ago TTM
Free cash flow
$-547,000
-172.7% vs prior year
EPS (TTM)
$0.17
+25.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
10.64M
+0.4% vs prior year
Net cash
$3.77M
as of Sep 30, 2026
Operating margin
8.5%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- NEPH (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South Orange, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1196298
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $18.8M | $14.2M | $14.2M | $10.0M | $10.2M |
| Operating income | $1.1M | $6,000 | -$1.6M | -$4.3M | -$3.3M |
| Net income | $1.2M | $74,000 | — | — | -$3.9M |
| Diluted EPS | $0.11 | $0.01 | -$0.15 | — | — |
| Operating cash flow | $1.6M | -$492,000 | $827,000 | -$3.2M | -$1.4M |
| Free cash flow | — | -$547,000 | $752,000 | -$3.4M | -$1.5M |
| Total assets | $13.6M | $11.2M | $11.9M | $11.0M | $17.6M |
| Total liabilities | $3.4M | $2.6M | $3.5M | $2.1M | $2.9M |
| Stockholders' equity | $10.2M | $8.6M | $8.4M | $8.9M | $14.7M |
| Cash and investments | $5.4M | $3.8M | $4.3M | $3.6M | $7.0M |
| Total debt | $1.1M | $1.4M | $1.8M | $1.1M | $343,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 13, 2026 | Oct 13, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 15, 2026 | Jun 12, 2026 |
All 1005 Nephros, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.